Abstract
Dyslipidemia resp. hypercholesterolemia is one of the most important risk factors for atherosclerotic vascular disease (ASKVO). New expert recommendations for the treatment of dyslipidemia, developed in 2019 in collaboration with the European Society of Cardiology (ESC) and the European Society for Atherosclerosis (EAS), provide new information on how to stratify and reduce our patients' cardiovascular (CV) risk based on evidence-based medicine.
In addition to regimen measures, statins remain the basis of hypolipidemic treatment. Ezetimibe and biologic therapy for hypercholesterolemia are given more space.
New and promising drugs in the treatment of dyslipidemia (especially bempedic acid and inclisirane) have not yet been included in expert recommendations.